Sector Gamma As
Sector Gamma As reported 40 US-listed holdings worth $461.0 million in its 13F for the quarter ended 30 June 2026, filed 12 August 2026. Its largest: Bristol-Myers Squibb Co. (9.1%), Merck & Co., Inc. (6.0%) and Medtronic plc (6.0%). Against the quarter before, it opened 7 positions, added to 19, trimmed 11 and sold out of 9.
The 14 largest of its 40 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +15.0% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 7
- Thermo Fisher Scientific Inc. TMO$16.8 million
- Regeneron Pharmaceuticals, Inc. REGN$9.8 million
- Ascendis Pharma A/s ASND$5.7 million
- Boston Scientific Corp. BSX$5.2 million
- Travere Therapeutics Inc. TVTX$4.5 million
- Cytokinetics Inc. CYTK$3.8 million
- Intellia Therapeutics Inc. NTLA$3.1 million
Added to 19
- IQVIA Holdings Inc. IQV+37,714 shares · +94%
- Medtronic plc MDT+71,755 shares · +26%
- Abbott Laboratories ABT+59,912 shares · +68%
- GE HealthCare Technologies Inc. GEHC+81,445 shares · +64%
- Qiagen NV Ord Shares QGEN+125,269 shares · +77%
- Biomarin Pharmaceutical Inc. BMRN+55,000 shares · +23%
- Dexcom Inc. DXCM+46,000 shares · +82%
- Bio-Rad Laboratories, Inc. BIO+9,600 shares · +40%
and 11 more in the table below
Trimmed 11
- Biogen Inc. BIIB-35,933 shares · -40%
- Amgen Inc. AMGN-20,874 shares · -44%
- Bruker Corp. BRKR-101,658 shares · -40%
- Bristol-Myers Squibb Co. BMY-101,786 shares · -12%
- Merck & Co., Inc. MRK-43,332 shares · -17%
- Cardinal Health Inc. CAH-14,208 shares · -26%
- Incyte Corp. INCY-29,757 shares · -15%
- Pfizer Inc. PFE-87,170 shares · -8%
and 3 more in the table below
Sold out of 9
- UnitedHealth Group Inc. UNH$9.9 million last quarter
- Gilead Sciences, Inc. GILD$7.4 million last quarter
- Lantheus Holdings, Inc. LNTH$7.1 million last quarter
- Ascendis Pharma A/s ASND$4.9 million last quarter
- Humana Inc. HUM$3.3 million last quarter
- Bridgebio Pharma Inc. BBIO$3.3 million last quarter
- Denali Therapeutics Inc. DNLI$3.1 million last quarter
- Cogent Biosciences Inc. COGT$3.1 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Bristol-Myers Squibb Co. BMY | 726.1K | $41.8 million | 9.08% | -101.8K |
| Merck & Co., Inc. MRK | 217.0K | $27.9 million | 6.05% | -43.3K |
| Medtronic plc MDT | 352.4K | $27.6 million | 5.98% | +71.8K |
| Pfizer Inc. PFE | 1.0M | $24.2 million | 5.25% | -87.2K |
| Incyte Corp. INCY | 170.8K | $19.4 million | 4.20% | -29.8K |
| Elevance Health, Inc. ELV | 44.5K | $17.2 million | 3.73% | +537 |
| Biomarin Pharmaceutical Inc. BMRN | 294.9K | $16.9 million | 3.66% | +55.0K |
| Thermo Fisher Scientific Inc. TMO | 33.6K | $16.8 million | 3.65% | new |
| CVS Health Corp. CVS | 155.3K | $16.1 million | 3.49% | +20.0K |
| IQVIA Holdings Inc. IQV | 77.9K | $15.1 million | 3.27% | +37.7K |
| Ionis Pharmaceuticals Inc. IONS | 189.5K | $15.0 million | 3.26% | +20.0K |
| Becton Dickinson & Co. BDX | 93.2K | $14.1 million | 3.06% | +10.6K |
| Abbott Laboratories ABT | 147.4K | $13.4 million | 2.90% | +59.9K |
| GE HealthCare Technologies Inc. GEHC | 207.9K | $13.3 million | 2.89% | +81.4K |
| Zimmer Biomet Holdings, Inc. ZBH | 142.3K | $12.3 million | 2.66% | -13.5K |
| Biogen Inc. BIIB | 54.2K | $11.7 million | 2.54% | -35.9K |
| Qiagen NV Ord Shares QGEN | 287.6K | $11.2 million | 2.44% | +125.3K |
| Centene Corp. CNC | 162.4K | $10.4 million | 2.26% | no change |
| Regeneron Pharmaceuticals, Inc. REGN | 15.8K | $9.8 million | 2.13% | new |
| Bio-Rad Laboratories, Inc. BIO | 33.4K | $9.8 million | 2.12% | +9.6K |
| Cardinal Health Inc. CAH | 40.7K | $9.7 million | 2.10% | -14.2K |
| Amgen Inc. AMGN | 26.3K | $9.5 million | 2.06% | -20.9K |
| Bruker Corp. BRKR | 152.4K | $9.2 million | 1.99% | -101.7K |
| Avantor, Inc. AVTR | 906.1K | $9.0 million | 1.95% | +210.7K |
| PTC Therapeutics, Inc. PTCT | 100.0K | $8.2 million | 1.77% | +25.0K |
| Labcorp Holdings Inc. LH | 26.0K | $7.3 million | 1.58% | +7.0K |
| Dexcom Inc. DXCM | 102.1K | $6.9 million | 1.49% | +46.0K |
| Ascendis Pharma A/s ASND | 21.3K | $5.7 million | 1.23% | new |
| Edwards Lifesciences Corp. EW | 60.4K | $5.5 million | 1.19% | no change |
| Syndax Pharmaceuticals Inc. SNDX | 241.7K | $5.3 million | 1.15% | -44.3K |
| Boston Scientific Corp. BSX | 121.1K | $5.2 million | 1.12% | new |
| Kura Oncology Inc. KURA | 433.0K | $4.8 million | 1.03% | +21.2K |
| Travere Therapeutics Inc. TVTX | 80.0K | $4.5 million | 0.99% | new |
| Crinetics Pharmaceuticals in CRNX | 114.6K | $4.3 million | 0.93% | +20.4K |
| Tandem Diabetes Care Inc. TNDM | 267.1K | $4.0 million | 0.87% | no change |
| Iovance Biotherapeutics Inc. IOVA | 968.5K | $4.0 million | 0.87% | +68.5K |
| Cytokinetics Inc. CYTK | 45.0K | $3.8 million | 0.83% | new |
| Organon & Co. OGN | 270.8K | $3.7 million | 0.80% | -105.2K |
| Ardelyx Inc. ARDX | 686.8K | $3.5 million | 0.76% | +170.7K |
| Intellia Therapeutics Inc. NTLA | 185.2K | $3.1 million | 0.68% | new |